Uysal Melis, Wehrle Chase J, Coppa Christopher, Kamath Suneel, Krishnamurthi Smitha, Martin Charles, Hag Mohamed El, Khalil Mazhar, Fujiki Masato, Schlegel Andrea, Miller Charles, Hashimoto Koji, Aucejo Federico, Kwon David Ch, Kim Jaekeun
Department of General Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Cleveland Clinic, Imaging Institute, Cleveland, OH, USA.
Exp Hematol Oncol. 2025 Feb 25;14(1):20. doi: 10.1186/s40164-025-00604-z.
Histotripsy is a novel, non-invasive, non-ionizing, and non-thermal ablation technique that disrupts tumors using acoustic cavitation. We report the first use of Histotripsy as bridging therapy prior to liver transplant for hepatocellular carcinoma (HCC) treated with histotripsy.
A 59-year-old woman presented with Metabolic-Associated Steatotic Liver Disease (MASLD) cirrhosis (labMELD = 14), hepatic encephalopathy, and a single 2 cm OPTN V lesion in the left lateral segment consistent with HCC. The patient underwent histotripsy treatment of the lesion as bridging therapy before receiving liver transplantation. Histopathology analysis of the explanted liver showed total necrosis of the treated area, with no residual viable tissue tumor.
This case demonstrates the potential utility of histotripsy as an effective bridging therapy for patients with combined cirrhosis and hepatocellular carcinoma (HCC) awaiting liver transplantation, with complete tumor necrosis on explant pathology demonstrating its therapeutic efficacy.
组织粉碎术是一种新型的非侵入性、非电离且非热消融技术，利用声空化作用破坏肿瘤。我们报告了首次将组织粉碎术用作肝细胞癌（HCC）肝移植前的桥接治疗，该肝细胞癌采用组织粉碎术进行治疗。
一名59岁女性，患有代谢相关脂肪性肝病（MASLD）肝硬化（实验室MELD评分=14）、肝性脑病，在左外侧段有一个2厘米的符合HCC的OPTN V期病变。该患者在接受肝移植前，对病变进行了组织粉碎术治疗作为桥接治疗。移植肝脏的组织病理学分析显示，治疗区域完全坏死，无残留存活组织肿瘤。
本病例证明了组织粉碎术作为等待肝移植的合并肝硬化和肝细胞癌（HCC）患者的有效桥接治疗的潜在效用，移植病理显示肿瘤完全坏死证明了其治疗效果。
